Swiss hepatitis C sufferers to get full access to expensive drug

The Federal Office of Public Health has announced that it will make the hepatitis C drug Zepatier available to all patients from July 1. The 12-week treatment costs CHF31,000 ($31,952) per patient and was previously only available to those with an advanced form of the disease. Zepatier is produced by pharma company Merck Sharp & Dohme and is a unique combination of drugs elbasvir and grazoprevir. It is effective for patients infected with genotype 1 a

ZEPATIER® now covered in Quebec for the treatment of chronic hepatitis C

KIRKLAND, QC, March 21, 2017 /CNW Telbec/ - Merck Canada Inc. today announced that ZEPATIER® (elbasvir/grazoprevir) will be listed among the drugs covered by Quebec's health insurance board, the Régie de l'assurance maladie du Québec (RAMQ), as of March 22. Quebec joins other jurisdictions that have approved the product for reimbursement under their public healthcare plans for chronic hepatitis C patients presenting with recognized criteria. Zepatier is i

The Week in Review: Feb 17, 2017 – Feb 24, 2017

Friday, February 24, 2017 News Recap Better Public Access to New HepC Meds Announced in Canada This week the pan-Canadian Pharmaceutical Alliance (pCPA), on behalf of participating federal, provincial and territorial public drug plans, concluded successful negotiations with three drug manufacturers to help jurisdictions expand access to publicly funded medications for the treatment of chronic hepatitis C. What this Means: Immediately following th...

Ontario and British Columbia expand treatment access to chronic hepatitis C (CHC) patients

Effective February 28, Ontario will become the first province to reimburse ZEPATIER®  (elbasvir/grazoprevir), a simple one pill, once daily, 12 week no ribavirin regimen for most patients, and will be followed by British Columbia on March 21 In addition to patients with liver fibrosis stage F2+, patients with liver fibrosis stage F0 and F1 with poor prognostic factors, who had no public access to a potential cure under existing public plans, a...

The Week in Review: Dec 9 – Dec 16, 2016

Friday, December 16, 2016 News Recap Canada Lawyers representing the pre86/post90 group in the Canadian tainted blood compensation debacle issued a MEDIA ADVISORY on December 14, 2016 seeking more people to interview for special hearings in Toronto on December 15 – 16.  The hearings will also be broadcast in courtrooms in Edmonton, Vancouver, and Montreal (Hepatitis-C Tainted Blood Victims Fight Ottawa for Solution to $220M Fund Shortfall). Also in ...

NZ: Zepatier Now Approved in New Zealand

15 December 2016, Merck Sharp & Dohme (New Zealand) Ltd (MSD) today announced ZEPATIER® (elbasvir/grazoprevir) has been registered by Medsafe for the treatment of chronic Hepatitis C – genotype 1, 3* and 4 infection in adults. MSD New Zealand Director, Mr Paul Smith, adds, “Although ZEPATIER is now registered, it is not yet funded by PHARMAC. We will continue to work with PHARMAC in order to provide access to ZEPATIER for all appropriate G1, G3 and G4...

Patient input is requested by BCPharmaCare for Merck’s MK2: Zepatier (grazoprevir / elbasvir)

Zepatier™ (grazoprevir / elbasvir [± ribavirin]) Merck’s combo was approved by the FDA in January: http://www.mercknewsroom.com/news-release/prescription-medicine-news/merck-receives-fda-approval-zepatier-elbasvir-and-grazoprevi and was also approved in Canada for genotypes 1, 3 and 4 in early February: http://hepcbc.ca/2016/02/merck-receives-approval-of-zepatier-elbasvirgrazoprevir-in-canada-for-the-treatment-of-chronic-hepatitis-c-for-patients-...

PATIENT GROUP SUBMISSIONS to BC PharmaCare, CADTH, & PMPRB

PATIENT GROUP SUBMISSIONS to BC PharmaCare, CADTH, & PMPRB Whenever we are asked to contribute a patient group submission about a hepatitis-C or hepatitis-B related product, we do so. We contribute as a patient group to reviews by both BC PharmaCare (to determine whether BC PharmaCare patients will be reimbursed for the drugs) and CADTH (federal level – to determine whether the drugs will be available in Canada). Occasionally we also submit patien

Merck to Present New Findings from Chronic Hepatitis C Clinical Development Programs at The International Liver CongressTM 2016

Presentations Include Results from Phase 3 Study Evaluating ZEPATIER™ (elbasvir and grazoprevir) Compared to Sofosbuvir-Containing Regimen, and Results from Studies in Difficult-to-Treat PopulationsMarch 30, 2016 07:00 AM Eastern Daylight TimeKENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced the planned presentations of data from the company’s broad chronic hepatitis C virus (HCV) cli

Current Treatments

Current HCV Treatments in BC as of March 2019 IMPORTANT: As of March 13, 2018,  anyone in B.C. living with this now-curable virus will have a choice of several treatment options – all of which are fully funded under BC PharmaCare, and all restrictions based on disease level have been removed. There are many drug combinations available for treating hepatitis C in Canada which are also covered by BC Pharmacare.  Older combinations involved the use of i